v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Operating Activities    
Net income before allocation to noncontrolling interests $ 26,404 $ 18,633
Discontinued operations––net of tax 4 (248)
Net income from continuing operations before allocation to noncontrolling interests 26,400 18,881
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:    
Depreciation and amortization 3,545 3,856
Asset write-offs and impairments 287 93
Deferred taxes from continuing operations (3,399) (3,610)
Share-based compensation expense 508 686
Benefit plan contributions in excess of expense/income (532) (1,933)
Other adjustments, net 1,481 (1,848)
Other changes in assets and liabilities, net of acquisitions and divestitures (7,605) 10,867
Net cash provided by operating activities from continuing operations 20,685 26,993
Net cash provided by/(used in) operating activities from discontinued operations 0 (327)
Net cash provided by operating activities 20,685 26,666
Investing Activities    
Purchases of property, plant and equipment (2,235) (1,709)
Purchases of short-term investments (29,701) (26,280)
Proceeds from redemptions/sales of short-term investments 35,087 15,852
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less (10,877) (7,152)
Purchases of long-term investments (1,627) (861)
Proceeds from redemptions/sales of long-term investments 446 569
Acquisition of business, net of cash acquired (6,225) 0
Dividends received from Haleon/GSK Consumer Healthcare JV (Note 2C) 3,960 0
Other investing activities, net (200) (370)
Net cash provided by/(used in) investing activities from continuing operations (11,373) (19,951)
Net cash provided by/(used in) investing activities from discontinued operations 0 (8)
Net cash provided by/(used in) investing activities (11,373) (19,960)
Financing Activities    
Proceeds from short-term borrowings 3,887 0
Payments on short-term borrowings (3,887) (1)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less 870 265
Proceeds from issuance of long-term debt 0 997
Payments on long-term debt (1,609) (1,001)
Purchases of common stock (2,000) 0
Cash dividends paid (6,738) (6,540)
Other financing activities, net (342) (185)
Net cash provided by/(used in) financing activities (9,819) (6,465)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents (139) (32)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents (646) 209
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period 1,983 1,825
Cash and cash equivalents and restricted cash and cash equivalents, at end of period 1,338 2,034
Cash paid/(received) during the period for:    
Income taxes 4,919 2,943
Interest paid 1,121 1,205
Interest rate hedges 28 (26)
Non-cash transaction:    
Right-of-use assets obtained in exchange for lease liabilities $ 463 $ 1,552